Written by Andrii Buvailo for ‘Where Technology Meets Biology’ Newsletter
Published on May 6, 2022
An excerpt from the original article is posted below:
Artificial intelligence (AI) is undoubtedly a big deal in the pharmaceutical industry, bringing the unprecedented abilities of modeling biology at a scale of not just separate biological processes, but whole cells and even tissues and organs (e.g. “network biology”, multi omics modeling, etc).
In previous issues of this newsletter we have discussed not once various drug design companies that created sophisticated AI-drive platforms for novel target discovery, lead generation, NLP-supported drug repurposing, biomarker discovery, and clinical trial improvement (e.g. better patient stratification, predicting drug responders vs. non-responders based on unique molecular markers, etc).
…
Dr. Basem Goueli, a key opinion leader in Hematology and Oncology, expanded on this topic in his comment for BiopharmaTrend channel:
Protean BioDiagnostics is a new entrant in this space.
And a bunch of others I'm missing at this moment. Indeed, many institutions have their own genomics and proteomics facilities, including some outside of academia (e.g. Intermountain Health). This same phenomenon is coming to oncology, but it will be much more complicated. After all, there are numerous protein posttranslational modifications that are going to be very difficult to fully account for with proteomics.”